RE:RE:RE:RE:RE:RE:Her2-positive brain metastasesLol. No, prophetoffacts, focused ultrasound (FUS) does not sound like a "strategic partner." Why would Bioasis want FUS? Bioasis can already get drugs into the brain without all the fuss of FUS. Your posts are moving from the ridiculous to the sublime. You can't save yourself with this one, prophetoffacts.
About the details you're asking for about FUS, you go find them. You're the one touting FUS. What, you want me to make an argument for you?
The cost of Herceptin per year in Canada is about $25,000 for stage 1 breast cancer. It can approach $50,000 if it has metastasized (stage 4).
FUS requires Herceptin dosing AND the use of significant hospital space, time, personnel and expensive equipment. What would it cost per year for regular doses? $250,000? $500,000. I'll place the search for that information into your hands, prophetofffacts.
But here's the rub. FUS is such a localized delivery method that it can't prevent metastases. Delivery throughout
the entire brain is required to kill off diffuse tumours, those little itty bitty 1-cell, 2-cell, 3-cell to n-cell metastases that cannot be detected with MRI or by any other means.
So, that would likely mean that FUS treatment would need to be repeated, at horrific costs and with declining efficacy (which is a characteristic of Herceptin treatment, not the delivery method).
So, I'm going to keep on responding to you, prophetofffacts. I haven't beaten you on this, prophetofffacts. I don't need to. xB3 is beating FUS and you're beating a dead horse.
Now, you mentioned taking on FUS as a strategic partner. FUS is a broadly based technology that is being used everywhere for multiple indications. It's great that some people may find benefit from its use with brain tumours. (
Have a look for yourself) at how ubiquitous it is.
But, prophetoffacts, why do you think Denali is in business? Why are other companies like Takeda using the transferrin receptor for LSDs? They know, just as Bioasis knows, that FUS can't do the same job that full distribution of drugs throughout the CNS can do. And they can't come close to competing on cost.
FUS is swell, it's interesting, but it can't compete with the delivery of drugs by receptor mediated transcytosis.